Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slipped 5.31% to $14.28 Monday, on what proved to be an all-around mixed ...

Corbus Pharmaceuticals Holdings Inc. closed $46.82 short of its 52-week high ($61.90), which the company achieved on July ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating on December 2.Pick the best ...

MetLife Investment Management LLC bought a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor ...

On Wednesday, B.Riley initiated coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and a price target of $85.00. The firm's coverage is based on the potential of... NORWOOD, MA ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Recursion Pharmaceuticals (RXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Alec Stranahan from Bank of America Securities ...

5 With marine-derived compounds being an innovative and obscure source of novel drug candidates for many diseases, it is no surprise that the global market for marine-derived pharmaceuticals has ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical findings from Ketamir-2, a novel oral ketamine analog. The new preclinical ...

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating ...